General ~ Ovarian Cancer Treatment
~ Genetics of Breast & Ovarian Cancer

References combining topics of medical, surgical and radiation ovarian cancer treatment

List was last updated on Dec 1, 2019 @ 8:21 am.


    • The OncoLifeS data-biobank for oncology: a comprehensive repository of clinical data, biological samples, and the patient's perspective.
    • Sidorenkov G, Nagel J, Meijer C, Duker JJ, Groen HJM, Halmos GB, Oonk MHM, Oostergo RJ, van der Vegt B, Witjes MJH, Nijland M, Havenga K, Maduro JH, Gietema JA, de Bock GH.
    • J Transl Med. 2019 Nov 14;17(1):374. doi: 10.1186/s12967-019-2122-x.
    • Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer before olaparib maintenance: Still getting any benefit? A case-control study.
    • Marchetti C, Rosati A, Scaletta G, Pietragalla A, Arcieri M, Ergasti R, Palluzzi E, Scambia G, Fagotti A.
    • Gynecol Oncol. 2019 Oct 9. pii: S0090-8258(19)31545-8. doi: 10.1016/j.ygyno.2019.09.020. [Epub ahead of print]
    • Can somatic BRCA2 status solve a case of olaparib monotherapy resistance?
    • Pietragalla A, Minucci A, Marchetti C, Scambia G, Fagotti A.
    • Int J Gynecol Cancer. 2019 Sep 19. pii: ijgc-2019-000757. doi: 10.1136/ijgc-2019-000757. [Epub ahead of print]
    • Available and emerging molecular markers in the clinical management of breast cancer.
    • Giridhar KV, Liu MC.
    • Expert Rev Mol Diagn. 2019 Sep 9. doi: 10.1080/14737159.2019.1664901. [Epub ahead of print]
    • Review
    • The role of BRCA1/2 in hereditary and familial breast and ovarian cancers.
    • Hawsawi YM, Al-Numair NS, Sobahy TM, Al-Ajmi AM, Al-Harbi RM, Baghdadi MA, Oyouni AA, Alamer OM.
    • Mol Genet Genomic Med. 2019 Jul 17:e879. doi: 10.1002/mgg3.879. [Epub ahead of print]
    • The clinical features associated with mutated BRCA1 and 2 genes in ovarian cancer patients.
    • Kubelac P, Vlad C, Berindan Neagoe I, Irimie A, Achimas Cadariu P.
    • J BUON. 2019 Jul-Aug;24(4):1538-1543.
    • AstraZeneca, Merck's Lynparza, Myriad Genetics' BRCA Test Approved in Japan.
    • [No author given]
    • GenomeWeb. 2019 Jun 19.
    • European Commission Approves Lynparza for Advanced Ovarian Cancer With BRCA Mutations.
    • [No author given]
    • Precision Oncology News (GenomeWeb). 2019 Jun 18.
    • Prognostic factors value of germline and somatic brca in patients undergoing surgery for recurrent ovarian cancer with liver metastases.
    • Gallotta V, Conte C, D'Indinosante M, Capoluongo E, Minucci A, De Rose AM, Ardito F, Giuliante F, Di Giorgio A, Zannoni GF, Fagotti A, Margreiter C, Scambia G, Ferrandina G.
    • Eur J Surg Oncol. 2019 Jun 13. pii: S0748-7983(19)30517-7. doi: 10.1016/j.ejso.2019.06.023. [Epub ahead of print]
    • Frequency of germline mutations in BRCA1 and BRCA2 in ovarian cancer patients and their effect on treatment outcome.
    • Ashour M, Ezzat Shafik H.
    • Cancer Manag Res. 2019 Jul 8;11:6275-6284. doi: 10.2147/CMAR.S206817. eCollection 2019.
    • Increased risk of brain metastases in ovarian cancer patients with BRCA mutations.
    • Ratner E, Bala M, Louie-Gao M, Aydin E, Hazard S, Brastianos PK.
    • Gynecol Oncol. 2019 Jun;153(3):568-573. doi: 10.1016/j.ygyno.2019.03.004. Epub 2019 Mar 12.
    • Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data.
    • Cohen PA, Powell A, Böhm S, Gilks CB, Stewart CJR, Meniawy TM, Bulsara M, Avril S, Brockbank EC, Bosse T, de Azevedo Focchi GR, Ganesan R, Glasspool RM, Howitt BE, Kim HS, Lee JY, Le ND, Lockley M, Manchanda R, Mandalia T, McCluggage WG, McNeish I, Midha D, Srinivasan R, Tan YY, van der Griend R, Yunokawa M, Zannoni GF; HGSC CR Collaborative Network (Supplementary 1), Singh N.
    • Gynecol Oncol. 2019 May 19. pii: S0090-8258(19)31181-3. doi: 10.1016/j.ygyno.2019.04.679. [Epub ahead of print]
    • Brain metastasis in epithelial ovarian cancer by BRCA1/2 mutation status.
    • Stasenko M, Cybulska P, Feit N, Makker V, Konner J, O'Cearbhaill RE, Alektiar KM, Beal K, Gardner GJ, Long Roche KC, Sonoda Y, Chi DS, Zivanovic O, Leitao MM Jr, Cadoo KA, Tew WP.
    • Gynecol Oncol. 2019 May 18. pii: S0090-8258(19)31229-6. doi: 10.1016/j.ygyno.2019.05.004. [Epub ahead of print]
    • Epithelial ovarian cancer: Evolution of management in the era of precision medicine.
    • Lheureux S, Braunstein M, Oza AM.
    • CA Cancer J Clin. 2019 May 17. doi: 10.3322/caac.21559. [Epub ahead of print]
    • Cancer Genomics for Oncologists: Cancer Risk and Management of BRCA1 and BRCA2 Carriers.
    • George A.
    • Curr Genet Med Rep. 2019 May 9. doi: 10.1007/s40142-019-00167-6. [Epub ahead of print]
    • Review
    • Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer.
    • Kim SI, Lee M, Kim HS, Chung HH, Kim JW, Park NH, Song YS.
    • J Ovarian Res. 2019 May 7;12(1):40. doi: 10.1186/s13048-019-0511-7.
    • Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE1 and RB1 genes.
    • da Costa AABA, do Canto LM, Larsen SJ, Ribeiro ARG, Stecca CE, Petersen AH, Aagaard MM, de Brot L, Baumbach J, Baiocchi G, Achatz MI, Rogatto SR.
    • BMC Cancer. 2019 May 6;19(1):422. doi: 10.1186/s12885-019-5622-4.
    • Hereditary ovarian cancers: state of the art.
    • Toss A, Molinaro E, Sammarini M, Del Savio MC, Cortesi L, Facchinetti F, Grandi G.
    • Minerva Med. 2019 May 6. doi: 10.23736/S0026-4806.19.06091-9. [Epub ahead of print]
    • Review
    • BRCA1-associated and sporadic ovarian carcinomas: outcomes of primary cytoreductive surgery or neoadjuvant chemotherapy.
    • Gorodnova T, Sokolenko A, Ni V, Ivantsov A, Kotiv K, Petrik S, Amelina I, Berlev I, Imyanitov E.
    • Int J Gynecol Cancer. 2019 May;29(4):779-786. doi: 10.1136/ijgc-2018-000175. Epub 2019 Mar 5.
    • AB0 Blood Group and Ovarian Cancer Survival.
    • Mandato VD, Torricelli F, Mastrofilippo V, Ciarlini G, Pirillo D, Annunziata G, Casali B, Abrate M, Sala GB, Aguzzoli L.
    • J Cancer. 2019 Apr 25;10(9):1949-1957. doi: 10.7150/jca.29272. eCollection 2019.
    • U.S. Food and Drug Administration-Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer: A Cost-Effectiveness Analysis.
    • Dottino JA, Moss HA, Lu KH, Secord AA, Havrilesky LJ.
    • Obstet Gynecol. 2019 Apr;133(4):795-802. doi: 10.1097/AOG.0000000000003171.
    • Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations.
    • Madariaga A, Lheureux S, Oza AM.
    • Cancers (Basel). 2019 Mar 23;11(3). pii: E416. doi: 10.3390/cancers11030416.
    • Epithelial ovarian cancer.
    • Lheureux S, Gourley C, Vergote I, Oza AM.
    • Lancet. 2019 Mar 23;393(10177):1240-1253. doi: 10.1016/S0140-6736(18)32552-2.
    • Review
    • The road to long-term survival: Surgical approach and longitudinal treatments of long-term survivors of advanced-stage serous ovarian cancer.
    • Javellana M, Hoppenot C, Lengyel E.
    • Gynecol Oncol. 2019 Feb;152(2):228-234. doi: 10.1016/j.ygyno.2018.11.007. Epub 2018 Nov 22.
    • Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status.
    • Gadducci A, Guarneri V, Peccatori FA, Ronzino G, Scandurra G, Zamagni C, Zola P, Salutari V.
    • J Ovarian Res. 2019 Jan 28;12(1):9. doi: 10.1186/s13048-019-0484-6.
    • Synchronous Ovarian and Breast Cancers with a Novel Variant in BRCA2 Gene: A Case Report.
    • Llinás-Quintero N, Cabrera-Florez E, Mendoza-Fandiño G, Matute-Turizo G, Vasquez-Trespalacios EM, Gallón-Villegas LJ.
    • Case Rep Oncol Med. 2019 Jan 6;2019:6958952. doi: 10.1155/2019/6958952. eCollection 2019.
    • Somatic mutations in BRCA1&2 in 201 unselected ovarian carcinoma samples - single institution study.
    • Kowalik A, Zalewski K, Kopczyński J, Siołek M, Lech M, Hińcza K, Kalisz J, Chrapek M, Zięba S, Furmańczyk J, Jedliński M, Chłopek M, Misiek M, Góźdź S.
    • Pol J Pathol. 2019;70(2):115-126. doi: 10.5114/pjp.2019.82905.
    • Detection of N-glycolylneuraminic acid biomarkers in sera from patients with ovarian cancer using an engineered N-glycolylneuraminic acid-specific lectin SubB2M.
    • Shewell LK, Wang JJ, Paton JC, Paton AW, Day CJ, Jennings MP.
    • Biochem Biophys Res Commun. 2018 Dec 9;507(1-4):173-177. doi: 10.1016/j.bbrc.2018.11.001. Epub 2018 Nov 8.

    Press: Novel Blood Test a Potential 'Game Changer' in Ovarian Cancer. (Medscape Oncology)

    • Principles of clinical management of ovarian cancer.
    • Gorodnova TV, Sokolenko AP, Kuligina E, Berlev IV, Imyanitov EN.
    • Chin Clin Oncol. 2018 Dec;7(6):56. doi: 10.21037/cco.2018.10.06.
    • BRCA Mutation Status to Personalize Management of Recurrent Ovarian Cancer: A Multicenter Study.
    • Marchetti C, De Leo R, Musella A, D'Indinosante M, Capoluongo E, Minucci A, Benedetti Panici P, Scambia G, Fagotti A.
    • Ann Surg Oncol. 2018 Nov;25(12):3701-3708. doi: 10.1245/s10434-018-6700-6. Epub 2018 Aug 20.

    Commentary:

    ASO Author Reflections: BRCA Mutation Status for Personalizing Management of Recurrent Ovarian Cancer-A Multicenter Study.

    • Secondary cytoreduction in ovarian cancer: who really benefits?
    • Giudice MT, D'Indinosante M, Cappuccio S, Gallotta V, Fagotti A, Scambia G, Petrillo M.
    • Arch Gynecol Obstet. 2018 Nov;298(5):873-879. doi: 10.1007/s00404-018-4915-1. Epub 2018 Sep 25.
    • Review
    • Radiomics of high-grade serous ovarian cancer: association between quantitative CT features, residual tumour and disease progression within 12 months.
    • Rizzo S, Botta F, Raimondi S, Origgi D, Buscarino V, Colarieti A, Tomao F, Aletti G, Zanagnolo V, Del Grande M, Colombo N, Bellomi M.
    • Eur Radiol. 2018 Nov;28(11):4849-4859. doi: 10.1007/s00330-018-5389-z. Epub 2018 May 8.
    • Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors.
    • Yang SYC, Lheureux S, Karakasis K, Burnier JV, Bruce JP, Clouthier DL, Danesh A, Quevedo R, Dowar M, Hanna Y, Li T, Lu L, Xu W, Clarke BA, Ohashi PS, Shaw PA, Pugh TJ, Oza AM.
    • Genome Med. 2018 Oct 31;10(1):81. doi: 10.1186/s13073-018-0590-x.
    • Germline and somatic genetic testing in ovarian cancer patients.
    • Chandrasekaran D, Manchanda R.
    • BJOG. 2018 Oct;125(11):1460. doi: 10.1111/1471-0528.15225. Epub 2018 May 10.
    • Commentary
    • Radiosensitization by the PARP inhibitor olaparib in BRCA1-proficient and deficient high-grade serous ovarian carcinomas.
    • Bi Y, Verginadis II, Dey S, Lin L, Guo L, Zheng Y, Koumenis C.
    • Gynecol Oncol. 2018 Sep;150(3):534-544. doi: 10.1016/j.ygyno.2018.07.002. Epub 2018 Jul 17.
    • Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management.
    • da Cunha Colombo Bonadio RR, Fogace RN, Miranda VC, Diz MDPE.
    • Clinics (Sao Paulo). 2018 Aug 20;73(suppl 1):e450s. doi: 10.6061/clinics/2018/e450s.
    • Outcome and Prognostic Impact of Surgical Staging in Serous Tubal Intraepithelial Carcinoma: A Cohort Study and Systematic Review.
    • Van der Hoeven NMA, Van Wijk K, Bonfrer SE, Beltman JJ, Louwe LA, De Kroon CD, Van Asperen CJ, Gaarenstroom KN.
    • Clin Oncol (R Coll Radiol). 2018 Aug;30(8):463-471. doi: 10.1016/j.clon.2018.03.036. Epub 2018 Apr 22.
    • Comparative clinicopathological and cytomorphological analyses of peritoneal carcinomatosis associated with metastatic breast carcinoma and primary peritoneal/ovarian carcinoma in patients with a history of breast carcinoma.
    • Na K, Lee JY, Sung JY, Kim GM, Koo JS, Kim HS.
    • Virchows Arch. 2018 Aug;473(2):165-175. doi: 10.1007/s00428-018-2390-5. Epub 2018 Jun 20.
    • Combined Treatment Modalities for High-Energy Proton Irradiation: Exploiting Specific DNA Repair Dependencies.
    • Deycmar S, Pruschy M.
    • Int J Part Ther. 2018 Summer;5(1):133-139. doi: 10.14338/IJPT-18-00020.1. Epub 2018 Sep 21.
    • Economic impact of olaparib on maintenance treatment of patients with BRCA-mutation positive, platinum-sensitive relapsing high-grade serous epithelial ovarian cancer in Spain.
    • Delgado-Ortega L, Ginés Rubió J, Garcías de España MDC, Carcedo D, Cordero Puentes L, Moya de Alarcón C.
    • Farm Hosp. 2018 May 1;42(3):95-102. doi: 10.7399/fh.10904.
    • Clinical study of hereditary ovarian cancer syndrome in Shandong province, East China.
    • Sheng X, Zhong Y, Lu C, Peng J, Yu H, Guo J.
    • Int J Gynaecol Obstet. 2018 May;141(2):234-239. doi: 10.1002/ijgo.12447. Epub 2018 Feb 14.
    • Role of tumor microenvironment in ovarian cancer pathobiology.
    • Ghoneum A, Afify H, Salih Z, Kelly M, Said N.
    • Oncotarget. 2018 Apr 27;9(32):22832-22849. doi: 10.18632/oncotarget.25126. eCollection 2018 Apr 27.
    • Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers.
    • Le Page C, Rahimi K, Köbel M, Tonin PN, Meunier L, Portelance L, Bernard M, Nelson BH, Bernardini MQ, Bartlett JMS, Bachvarov D, Gotlieb WH, Gilks B, McAlpine JN, Nachtigal MW, Piché A, Watson PH, Vanderhyden B, Huntsman DG, Provencher DM, Mes-Masson AM.
    • BMC Cancer. 2018 Mar 27;18(1):347. doi: 10.1186/s12885-018-4242-8.
    • Cardiovascular Concerns in BRCA1 and BRCA2 Mutation Carriers.
    • Gast KC, Viscuse PV, Nowsheen S, Haddad TC, Mutter RW, Wahner Hendrickson AE, Couch FJ, Ruddy KJ.
    • Curr Treat Options Cardiovasc Med. 2018 Mar 1;20(2):18. doi: 10.1007/s11936-018-0609-z.
    • Review
    • Prophylactic mastectomy for BRCA mutation carriers after ovarian cancer treatment: is it beneficial?
    • Kotsopoulos J, Narod SA.
    • Expert Rev Anticancer Ther. 2018 Mar;18(3):199-200. doi: 10.1080/14737140.2018.1424547. Epub 2018 Jan 8.
    • Management of hereditary breast and ovarian cancer.
    • Yamauchi H, Takei J.
    • Int J Clin Oncol. 2018 Feb;23(1):45-51. doi: 10.1007/s10147-017-1208-9. Epub 2017 Nov 28.
    • Review
    • Enhancing radiosensitisation of BRCA2-proficient and BRCA2-deficient cell lines with hyperthermia and PARP1-i.
    • Oei AL, Ahire VR, van Leeuwen CM, Ten Cate R, Stalpers LJA, Crezee J, Kok HP, Franken NAP.
    • Int J Hyperthermia. 2018 Feb;34(1):39-48. doi: 10.1080/02656736.2017.1324642. Epub 2017 May 19.
    • A salpingeal carcinoma revealed after prophylactic salpingoophorectomy in an asymptomatic BRCA1 carrier with breast malignancy.
    • Giannos A, Stavrou S, Douskos A, Drakakis P, Loutradis D.
    • Int J Surg Case Rep. 2018;52:107-110. doi: 10.1016/j.ijscr.2018.10.014. Epub 2018 Oct 12.
    • SMART Cancer Navigator: A Framework for Implementing ASCO Workshop Recommendations to Enable Precision Cancer Medicine.
    • Warner JL, Prasad I, Bennett M, Arniella M, Beeghly-Fadiel A, Mandl KD, Alterovitz G.
    • JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00292. Epub 2018 May 1.
    • Genetics of Breast and Gynecologic Cancers (PDQ®): Health Professional Version. Clinical Management of Carriers of BRCA Pathogenic Variants. Treatment Strategies. Ovarian cancer.
    • PDQ Cancer Genetics Editorial Board.
    • PDQ Cancer Information Summaries [Internet]. Bethesda, MD: National Cancer Institute. Updated 2017 Nov 30. Accessed 2017 Dec 8.
    • The roles of pathology in targeted therapy of women with gynecologic cancers.
    • Murali R, Grisham RN, Soslow RA.
    • Gynecol Oncol. 2017 Nov 23. pii: S0090-8258(17)31530-5. doi: 10.1016/j.ygyno.2017.11.020. [Epub ahead of print]
    • Review
    • BRCA mutations in the manifestation and treatment of ovarian cancer.
    • Pan Z, Xie X.
    • Oncotarget. 2017 May 30;8(57):97657-97670. doi: 10.18632/oncotarget.18280. eCollection 2017 Nov 14.
    • Treatment of recurrent ovarian cancer.
    • Pignata S, C Cecere S, Du Bois A, Harter P, Heitz F.
    • Ann Oncol. 2017 Nov 1;28(suppl_8):viii51-viii56. doi: 10.1093/annonc/mdx441.
    • Review, Conference abstract
    • High-Grade Serous Ovarian Cancer: Associations between BRCA Mutation Status, CT Imaging Phenotypes, and Clinical Outcomes.
    • Nougaret S, Lakhman Y, Gönen M, Goldman DA, Miccò M, D'Anastasi M, Johnson SA, Juluru K, Arnold AG, Sosa RE, Soslow RA, Vargas HA, Hricak H, Kauff ND, Sala E.
    • Radiology. 2017 Nov;285(2):472-481. doi: 10.1148/radiol.2017161697. Epub 2017 Jun 16.
    • Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer.
    • Garsed DW, Alsop K, Fereday S, Emmanuel C, Kennedy C, Etemadmoghadam D, Gao B, Gebski V, Garès V, Christie EL, Wouters MC, Milne K, George J, Patch AM, Li J, Mir Arnau G, Semple T, Gadipally SR, Chiew YE, Hendley J, Mikeska T, Zapparoli GV, Amarasinghe K, Grimmond S, Pearson JV, Waddell N, Hung J, Stewart CJR, Sharma R, Allan PE, Rambau PF, Traficante N, McNally O, Mileshkin L, Hamilton AL, Ananda S, Grossi M, Cohen PA, Leung YC, Rome RM, Beale PJ, Blomfield P, Friedlander M, Brand A, Dobrovic A, Köbel M, Harnett P, Nelson BH, Bowtell DDL, DeFazio A.
    • Clin Cancer Res. 2017 Oct 23. pii: clincanres.1621.2017. doi: 10.1158/1078-0432.CCR-17-1621. [Epub ahead of print]
    • Prognostic impact of germline mutations in inherited cancer syndromes.
    • Corso G, Feroce I, Intra M, Veronesi P, Sacchini V, Bonanni B, Galimberti V.
    • Future Oncol. 2017 Oct;13(24):2125-2127. doi: 10.2217/fon-2017-0296. Epub 2017 Oct 6.
    • Editorial, Review
    • BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
    • Petrillo M, Marchetti C, De Leo R, Musella A, Capoluongo E, Paris I, Benedetti Panici P, Scambia G, Fagotti A.
    • Am J Obstet Gynecol. 2017 Sep;217(3):334.e1-334.e9. doi: 10.1016/j.ajog.2017.05.036. Epub 2017 May 23.
    • Elevated Serum Level of CA125 Is a Biomarker That Can Be Used to Alter Prognosis Determined by BRCA Mutation and Family History in Ovarian Cancer.
    • Liu W, Wang Z, Ma J, Hou Y, Zhao J, Dong B, Tu S, Wang L, Guo Y.
    • Genet Test Mol Biomarkers. 2017 Sep;21(9):547-554. doi: 10.1089/gtmb.2017.0104. Epub 2017 Aug 11.
    • Final report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology, on a fact-finding questionnaire on the status of treatment of hereditary breast and ovarian cancer syndrome in Japan.
    • Satoh T, Takamatsu K, Takeshima N, Kobayashi H, Aoki D, Suzuki N.
    • J Obstet Gynaecol Res. 2017 Sep;43(9):1377-1380. doi: 10.1111/jog.13409. Epub 2017 Aug 17.
    • BRCA mutation in ovarian cancer: testing, implications and treatment considerations.
    • Neff RT, Senter L, Salani R.
    • Ther Adv Med Oncol. 2017 Aug;9(8):519-531. doi: 10.1177/1758834017714993. Epub 2017 Jun 19.
    • Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancer.
    • Bookman MA, Tyczynski JE, Espirito JL, Wilson TW, Fernandes AW.
    • Gynecol Oncol. 2017 Jul;146(1):58-63. doi: 10.1016/j.ygyno.2017.04.011. Epub 2017 Apr 26.
    • [Il ruolo di niraparib nel trattamento del carcinoma ovarico: attualità e prospettive.] [The role of niraparib in the treatment of ovarian cancer: actuality and perspectives]
    • Sabatucci I, Lorusso D.
    • Recenti Prog Med. 2017 Jun;108(6):265-268. doi: 10.1701/2715.27713.
    • Review, [Article in Italian]
    • [Innovations in the treatment of ovarian cancer. Analysis of the therapeutic development: from platinum to immunotherapy.]
    • Angius G, Sepe P, Papa A, Tomao S, Tomao F.
    • Recenti Prog Med. 2017 Jun;108(6):269-281. doi: 10.1701/2715.27714.
    • Review, [Article in Italian]
    • Traitement des rechutes tardives du cancer de l’ovaire. [Treatment for Platinum-Sensitive Relapses of Ovarian Cancer.]
    • Floquet A, Berton-Rigaud D, Ferron G, Freyer G, Hardy-Bessard AC, You B.
    • Bull Cancer. 2017 May;104 Suppl 1:S24-S31. doi: 10.1016/S0007-4551(17)30159-5.
    • Review, [Article in French]
    • A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers.
    • Reiss KA, Herman JM, Armstrong D, Zahurak M, Fyles A, Brade A, Milosevic M, Dawson LA, Scardina A, Fischer P, Hacker-Prietz A, Kinders RJ, Wang L, Chen A, Temkin S, Horiba N, Stayner LA, Siu LL, Azad NS.
    • Gynecol Oncol. 2017 Mar;144(3):486-490. doi: 10.1016/j.ygyno.2017.01.016. Epub 2017 Jan 18.
    • [Clinical significance and distribution of BRCA genes mutation in sporadic high grade serous ovarian cancer].
    • Liu WL, Wang ZZ, Zhao JZ, Hou YY, Wu XX, Li W, Dong B, Tong TT, Guo YJ.
    • Zhonghua Fu Chan Ke Za Zhi. 2017 Jan 25;52(1):26-31. doi: 10.3760/cma.j.issn.0529-567X.2017.01.007.
    • Article in Chinese; English Abstract
    • Prognostic significance of BRCA mutations in ovarian cancer: an updated systematic review with meta-analysis.
    • Xu K, Yang S, Zhao Y.
    • Oncotarget. 2017 Jan 3;8(1):285-302. doi: 10.18632/oncotarget.12306.
    • Overall Survival Following Neoadjuvant Chemotherapy vs Primary Cytoreductive Surgery in Women With Epithelial Ovarian Cancer: Analysis of the National Cancer Database.
    • Rauh-Hain JA, Melamed A, Wright A, Gockley A, Clemmer JT, Schorge JO, Del Carmen MG, Keating NL.
    • JAMA Oncol. 2017 Jan 1;3(1):76-82. doi: 10.1001/jamaoncol.2016.4411.
    • Olaparib (LYNPARZAO) Ovarian cancer: spare patients who are in remission.
    • [No authors listed]
    • Prescrire Int. 2017 Jan;26(178):9-12.
    • Germ line mutations associated with leukemias.
    • Porter CC.
    • Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):302-308.
    • Review
    • STIC-ing with what we know.
    • Chen LM.
    • Gynecol Oncol. 2016 Nov;143(2):227-228. doi: 10.1016/j.ygyno.2016.10.007.
    • Editorial
    • Prognostic implications of reproductive and lifestyle factors in ovarian cancer.
    • Poole EM, Konstantinopoulos PA, Terry KL.
    • Gynecol Oncol. 2016 Sep;142(3):574-87. doi: 10.1016/j.ygyno.2016.05.014. Epub 2016 May 29.
    • Review
    • The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type.
    • Witkowski L, Goudie C, Ramos P, Boshari T, Brunet JS, Karnezis AN, Longy M, Knost JA, Saloustros E, McCluggage WG, Stewart CJ, Hendricks WP, Cunliffe H, Huntsman DG, Pautier P, Levine DA, Trent JM, Berchuck A, Hasselblatt M, Foulkes WD.
    • Gynecol Oncol. 2016 Jun;141(3):454-60. doi: 10.1016/j.ygyno.2016.03.013. Epub 2016 Mar 19.
    • Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of ovarian cancer including primary peritoneal cancer and fallopian tube cancer.
    • Komiyama S, Katabuchi H, Mikami M, Nagase S, Okamoto A, Ito K, Morishige K, Suzuki N, Kaneuchi M, Yaegashi N, Udagawa Y, Yoshikawa H.
    • Int J Clin Oncol. 2016 Jun;21(3):435-46. doi: 10.1007/s10147-016-0985-x. Epub 2016 May 3.
    • Practice Guideline
    • Impact of Clinical Genetics Attendance at a Gynecologic Oncology Tumor Board on Referrals for Genetic Counseling and BRCA Mutation Testing.
    • Cohen PA, Nichols CB, Schofield L, Van Der Werf S, Pachter N.
    • Int J Gynecol Cancer. 2016 Jun;26(5):892-7. doi: 10.1097/IGC.0000000000000689.
    • Ovarian Cancer and BRCA1/2 Testing: Opportunities to Improve Clinical Care and Disease Prevention.
    • Karakasis K, Burnier JV, Bowering V, Oza AM, Lheureux S.
    • Front Oncol. 2016 May 11;6:119. doi: 10.3389/fonc.2016.00119. eCollection 2016.
    • Ovarian cancer in BRCA1 and BRCA2 gene mutation carriers: analysis of prognostic factors and survival.
    • Biglia N, Sgandurra P, Bounous VE, Maggiorotto F, Piva E, Pivetta E, Ponzone R, Pasini B.
    • Ecancermedicalscience. 2016 May 3;10:639. doi: 10.3332/ecancer.2016.639. eCollection 2016.
    • Characteristics of 10-year survivors of high-grade serous ovarian carcinoma.
    • Dao F, Schlappe BA, Tseng J, Lester J, Nick AM, Lutgendorf SK, McMeekin S, Coleman RL, Moore KN, Karlan BY, Sood AK, Levine DA.
    • Gynecol Oncol. 2016 May;141(2):260-3. doi: 10.1016/j.ygyno.2016.03.010. Epub 2016 Mar 11.
    • BRCA testing, treatment patterns and survival in platinum-sensitive recurrent ovarian cancer - an observational cohort study.
    • Unni SK, Schauerhamer MB, Deka R, Tyczynski JE, Fernandes AW, Stevens V, Brixner DI, Stenehjem DD.
    • J Ovarian Res. 2016 Mar 22;9(1):18. doi: 10.1186/s13048-016-0227-x.
    • BRCA2-positive spinal intramedullary ovarian metastatic disease: case report.
    • Ravindra VM, Mazur MD, Driscoll M, McEvoy S, Schmidt MH.
    • Spine J. 2016 Mar;16(3):e201-7. doi: 10.1016/j.spinee.2015.10.053. Epub 2015 Nov 10.
    • Case report
    • Comparison of effectiveness of treatment of patients with sporadic and germline BRCA1-related ovarian cancer.
    • Szatkowski W, Muzykiewicz K, Jasiówka M, Karolewski K, Kojs Z, Klimek M, Blecharz P.
    • Ginekol Pol. 2016;87(6):422-5. doi: 10.5603/GP.2016.0019.
    • Individualiserad behandling vid ovarialcancer kan bli möjlig.
    • Kjölhede P, Dahm-Kähler P, Tholander B, Åvall Lundqvist E.
    • Lakartidningen. 2015 Dec 8;112. pii: DLUF.
    • Why have ovarian cancer mortality rates declined? Part III. Prospects for the future.
    • Sopik V, Rosen B, Giannakeas V, Narod SA.
    • Gynecol Oncol. 2015 Sep;138(3):757-61. doi: 10.1016/j.ygyno.2015.06.019. Epub 2015 Jun 16.
    • Review
    • Clinical Sequencing Contributes to a BRCA-Associated Cancer Rediagnosis That Guides an Effective Therapeutic Course.
    • Chapman JS, Asthana S, Cade L, Chang MT, Wang Z, Zaloudek CJ, Ueda S, Collisson EA, Taylor BS.
    • J Natl Compr Canc Netw. 2015 Jul;13(7):835-45.
    • Current management of ovarian cancer.
    • Grabowski JP, Sehouli J.
    • Minerva Med. 2015 Jun;106(3):151-6. Epub 2015 Apr 22.
    • Review
    • Targeted therapy for hereditary cancer syndromes: hereditary breast and ovarian cancer syndrome, Lynch syndrome, familial adenomatous polyposis, and Li-Fraumeni syndrome.
    • Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V; Pan-Cancer Working Group.
    • Discov Med. 2014 Dec;18(101):331-9.
    • BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients - A study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD).
    • Ruscito I, Dimitrova D, Vasconcelos I, Gellhaus K, Schwachula T, Bellati F, Zeillinger R, Benedetti-Panici P, Vergote I, Mahner S, Cacsire-Tong D, Concin N, Darb-Esfahani S, Lambrechts S, Sehouli J, Olek S, Braicu EI.
    • Eur J Cancer. 2014 Aug;50(12):2090-8. doi: 10.1016/j.ejca.2014.05.001. Epub 2014 Jun 2.
    • Ovarian Cancer 101 for the Newly Diagnosed.
    • Ilana Cass.
    • FORCE. Be Empowered Webinars. 2014 Apr 11.
    • Predicting time to ovarian carcinoma recurrence using protein markers.
    • Yang JY, Yoshihara K, Tanaka K, Hatae M, Masuzaki H, Itamochi H; Cancer Genome Atlas (TCGA) Research Network, Takano M, Ushijima K, Tanyi JL, Coukos G, Lu Y, Mills GB, Verhaak RG.
    • J Clin Invest. 2013 Sep;123(9):3740-50. doi: 10.1172/JCI68509. Epub 2013 Aug 15.

    Erratum: Predicting time to ovarian carcinoma recurrence using protein markers (Journal of Clinical Investigation)

    • Outcome of BRCA1- compared with BRCA2-associated ovarian cancer: a nationwide study in the Netherlands.
    • Vencken PM, Reitsma W, Kriege M, Mourits MJ, de Bock GH, de Hullu JA, van Altena AM, Gaarenstroom KN, Vasen HF, Adank MA, Schmidt MK, van Beurden M, Zweemer RP, Rijcken F, Slangen BF, Burger CW, Seynaeve C.
    • Ann Oncol. 2013 Aug;24(8):2036-42. doi: 10.1093/annonc/mdt068. Epub 2013 Mar 29.
    • The different impact of BRCA mutations on the survival of epithelial ovarian cancer patients: a retrospective single-center experience.
    • Lorusso D, Cirillo F, Mancini M, Spatti GB, Grijuela B, Ditto A, Raspagliesi F.
    • Oncology. [2013 Aug;]85(2):122-7. doi: 10.1159/000353786. Epub 2013 Aug 13.
    • Hereditary gynaecological malignancies: advances in screening and treatment.
    • Folkins AK, Longacre TA.
    • Histopathology. 2013 Jan;62(1):2-30. doi: 10.1111/his.12028.
    • Review
    • Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer.
    • Liu G, Yang D, Sun Y, Shmulevich I, Xue F, Sood AK, Zhang W.
    • Pharmacogenomics. 2012 Oct;13(13):1523-35. doi: 10.2217/pgs.12.137.

    Press: Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer. (Medscape)

    • Key features of extrauterine pelvic serous tumours (fallopian tube, ovary, and peritoneum).
    • Delair D, Soslow RA.
    • Histopathology. 2012 Sep;61(3):329-39. doi: 10.1111/j.1365-2559.2011.04167.x. Epub 2012 Feb 28.
    • Review
    • [Clinical features and disease course in patients with BRCA1-dependent ovarian cancer].
    • Blecharz P, Szatkowski W, Bodzek M, Łuczyńska E.
    • Ginekol Pol. 2012 May;83(5):353-6.
    • [Article in Polish]
    • Clinicopathologic characteristics and survival in BRCA1- and BRCA2-related adnexal cancer: are they different?
    • Reitsma W, de Bock GH, Oosterwijk JC, ten Hoor KA, Hollema H, Mourits MJ.
    • Int J Gynecol Cancer. 2012 May;22(4):579-85. doi: 10.1097/IGC.0b013e31823d1b5c.
    • Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer.
    • Fleming ND, Agadjanian H, Nassanian H, Miller CW, Orsulic S, Karlan BY, Walsh CS.
    • Cancer. 2012 Feb 1;118(3):689-97. doi: 10.1002/cncr.26329. Epub 2011 Jul 12.
    • Clinical characteristics and outcomes of BRCA-associated ovarian cancer: genotype and survival.
    • Liu J, Cristea MC, Frankel P, Neuhausen SL, Steele L, Engelstaedter V, Matulonis U, Sand S, Tung N, Garber JE, Weitzel JN.
    • Cancer Genet. 2012 Jan-Feb;205(1-2):34-41. doi: 10.1016/j.cancergen.2012.01.008.